Risk of tuberculosis and hepatitis B reactivation during adalimumab use in the treatment of hidradenitis suppurativa

Abstract Recently, adalimumab has become an important drug frequently used by dermatologists in the treatment of Hidradenitis suppurativa. While there are many publications by rheumatologists about the risk of hepatitis B and tuberculosis reactivation, the literature on reactivation in the treatment...

Full description

Bibliographic Details
Published in:Scientific Reports
Main Authors: Ömer Karakoyun, Erhan Ayhan
Format: Article
Language:English
Published: Nature Portfolio 2025-09-01
Subjects:
Adalimumab
Hidradenitis suppurativa (HS)
Hepatitis B
Tuberculosis
Reactivation
Online Access:https://doi.org/10.1038/s41598-025-95096-6

Internet

https://doi.org/10.1038/s41598-025-95096-6

Similar Items